Introduction:

Complete360®, our flagship platform for clinical proteomics applications at the molecular diagnostics level, is a groundbreaking achievement in the field of human plasma proteomics. It is developed from over 17 years of dedicated research and innovation since 2007. With an unmatched foundation in mass spectrometry, our platform represents the culmination of extensive expertise, having meticulously analyzed over 1 million human plasma samples.

This unparalleled experience has enabled us to construct the largest and most comprehensive human plasma proteomics diagnostics platform through the recursive optimizations. Complete360® stands as a testament to our commitment to excellence, offering an unmatched resource for biomarker discovery, disease diagnosis, and therapeutic guidance. By leveraging our long optimized platforms and advanced analytical capabilities, we provide our clients with insights of unparalleled depth and accuracy and extreme reproducibility (quantification CV <8%) in plasma proteomics analysis, paving the way for personalized medicine and molecular diagnostics feasibilities, as well as transformative health care solutions.

With Complete360®, we not only deliver precision and reliability but also embody a legacy of innovation and discovery that propels the field of proteomics into its clinical applications. Please contact us and start a project with Complete Omics in harnessing the power of Complete360® to unlock the full potential of biomarker research and clinical application, setting new standards for patient care and therapeutic success.

Sample types we accept:

Biofluids, such as plasma*, serum*, saliva, tear, etc.

*We provide High Abundance Protein Depletion Service to significantly (100-500 folds) increase the depth of your biofluid proteomics analysis by removing top abundant proteins from your samples. Read more for details​.

Customized sample types (please contact us to discuss)

Strategic Partnership with M20 Genomics, Advancing Single-Cell Multi-Omics for Precision Medicine

August 20, 2024 | BALTIMORE –  Complete Omics is thrilled to announce an electrifying partnership with M20 Genomics, a trailblazer in single-cell and spatial transcriptomics! Together, these industry leaders are…

Read more

Exciting News | Valid-NEO® Platform Secures U.S. Patent

May 12, 2024 | BALTIMORE –  Complete Omics is thrilled to announce that our Valid-NEO® platform’s “Method and System for Neoantigen Analysis” has been granted a U.S. patent after a rigorous…

Read more

Complete Omics Inc. Proudly Welcomes Proteomics Luminary Dr. Hui Zhang as Chief Scientific Officer

January 12, 2024 | BALTIMORE –  Complete Omics’ Clinical Proteomics team are thrilled to announce that Dr. Hui Zhang, a distinguished figure in the realm of proteomics, has joined the…

Read more

Some of our impacts